Comparison of Effects of Buffered and Enteric-coated Forms of Aspirin on Platelet Aggregation in Patients With Diabetes Mellitus and Chronic Coronary Syndrome

Prior treatment

• Patients with bronchial asthma induced by taking salicylates and non-steroidal anti-inflammatory drugs;
• Patients with future planned coronary bypass surgery, percutaneous coronary intervention or any other revascularisation in which dual antiplatelet therapy should be administered;

Other illness

• Patients with conditions that require anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valves, etc.) or dual antiplatelet therapy (recent percutaneous coronary intervention, coronary bypass, myocardial infarction, cerebral infarction, etc.);
• Patients with a history of intracranial haemorrhage;
• Patients with any contraindications to acetylsalicylic acid, including known allergy or hypersensitivity to acetylsalicylic acid, drug excipients, or other nonsteroidal anti-inflammatory drugs;
• Patients with ongoing haemorrhage;
• Patients with active psychiatric, infectious diseases and cancer;
• Patients with chronic heart failure of New York Heart Association (NYHA) functional class III-IV (FC);

Lab values

• Patients with severe renal disease (serum creatinine\>2.5 mg/dL \[221 micromol/L\]) or estimated creatinine clearance \<30 mL/min;
• Patients with congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

Other

• Patients with erosive-ulcerous lesions of the gastrointestinal tract (in the exacerbation phase);
• Pregnant, lactating women;
• Patients with known coagulopathies, thrombocytopathies, thrombocytopenia;
• Patients taking methotrexate (more than 15 mg per week).

• Patients (men and women) aged 18 years and older with chronic coronary syndrome and DM2;
• Patient is taking Cardiomagnil (75 mg/day) - buffered form ASA or Aspirin® Cardio (100 mg/day) or Thrombo ACC® (100 mg/day) enteric-coated form ASA on a regular basis;
• Signed informed consent.